Skip to main content

Table 3 Stratification of estimated CdM effect size on immune cells

From: Mesenchymal stromal cell conditioned media for lung disease: a systematic review and meta-analysis of preclinical studies

 

# Studies

# Comparisons

SMD (95% CI)

% Weight

I^2

p*

p**

Disease

       

 Asthma

3

41

0.79 (0.59, 0.10)

63.93

72.80

0.00

0.59

 BPD

1

4

3.74 (3.13, 4.36)

7.07

85.50

0.00

 ARDS

2

14

0.72 (0.41, 1.04)

26.78

77.00

0.00

 PH

1

2

2.42 (1.32, 3.52)

2.21

0.00

0.97

Animal model/species

       

 Mouse

5

40

1.61 (1.40, 1.82)

60.98

79.60

0.00

0.00

 Rat

2

21

0.10 (-0.17, 0.36)

39.02

54.90

0.00

Strain

       

 C57/BL6

4

36

1.33 (1.11, 1.56)

53.91

70.30

0.00

0.00

 FVB

1

4

3.74 (3.13, 4.36)

7.07

85.50

0.00

 Wistar

2

21

0.10 (-0.17, 0.36)

39.02

54.90

0.00

Gender

       

 Male

5

55

0.77 (0.60, 0.95)

90.71

73.50

0.00

0.01

 Mixed

1

4

3.74 (3.13, 4.36)

7.07

85.50

0.00

 Not reported

1

2

2.42 (1.32, 3.52)

2.21

0.00

0.97

Age

       

 Neonatal

1

4

3.74 (3.13, 4.36)

7.07

85.50

0.00

0.00

 Adult

5

53

0.80 (0.70, 1.06)

84.90

74.50

0.00

 Not reported

1

4

0.12 (-0.46, 0.70)

8.03

0.00

0.45

Intervention characteristics

       

Asthma

      

0.18

 Ovalbumin

2

21

0.10 (-0.17, 0.36)

39.02

54.90

0.00

 Aspergillus exposure

1

19

1.89 (1.56, 2.21)

24.91

41.60

0.03

ARDS

      

 LPS

2

14

0.73 (.41, 1.04)

26.78

77.00

0.00

BPD

      

 75% hyperoxia

1

4

3.74 (3.13, 4.36)

7.07

85.50

0.00

PH

      

 Hypoxia

1

2

2.42 (1.32, 3.52)

2.21

0.00

0.97

Source

       

 Bone marrow

6

57

1.10 (0.93, 1.27)

91.97

81.40

0.00

 

 Adipose tissue

1

4

0.12 (-0.46, 0.70)

8.03

0.00

0.45

0.14

Origin

       

 Allogenic

7

61

1.02 (0.86, 1.18)

100.00

80.90

0.00

0.00

Dose

       

 200ul

2

24

1.46 (1.17, 1.74)

32.95

63.20

0.00

0.00

 50ul

4

27

0.74 (0.50, 0.97)

48.30

86.30

0.00

 30ul

1

10

0.99 (1.17, 1.74)

18.75

81.20

0.00

Delivery

       

 Intravenous

5

43

1.19 (1.00, 1.39)

68.50

80.20

0.00

0.08

 Intratracheal

2

18

0.64 (0.35, 0.93)

31.50

81.70

0.00

Timing of treatment

       

 <72hr

5

37

0.42 (0.22, 0.62)

68.01

70.80

0.00

0.00

 >72hr

2

24

2.30 (2.01, 2.59)

31.99

71.40

0.00

  1. *p refers to p value within subgroups
  2. **p refers to p value between subgroups